Group 1: Peng Bo Shi (鹏博士) Case - Peng Bo Shi failed to disclose related party transactions as required [8] - Peng Bo Shi did not disclose significant contracts as mandated [8] - From 2012 to 2022, Peng Bo Shi's annual reports contained false records, including a profit inflation of 42,456,137.95 yuan in 2012, which accounted for 17.43% of that year's total profit [6][8] - Annual reports from 2012 to 2015 inflated assets, with the 2016 report inflating assets and profits by 162,000,000 yuan, representing 17.48% of that year's total profit [6][8] - From 2020 to 2022, Peng Bo Shi's annual reports reduced net assets by 196,000,000 yuan, which constituted 21.77%, 14.27%, and 18.51% of the net assets at the end of 2020, 2021, and 2022 respectively [2][6] Group 2: Investor Compensation - Investors who purchased Peng Bo Shi stock between April 12, 2013, and July 18, 2023, and sold or held the stock after July 18, 2023, may initiate claims for compensation [7] - The law firm representing investors in the Peng Bo Shi case has received a mediation agreement, allowing some investors to receive compensation [1][7] Group 3: Ning Ke Biological (宁科生物) Case - Ning Ke Biological's 2022 annual report contained false records, inflating revenue by 76,594,100 yuan and total profit by 77,222,000 yuan, which represented 11.25% and 46.59% of the respective totals [9] - The company failed to timely disclose significant events, including major debts and the freezing of key bank accounts [10][11] - Investors who bought Ning Ke Biological stock between November 22, 2022, and April 6, 2023, and sold or held the stock after April 6, 2023, as well as those who bought between April 28, 2023, and October 31, 2024, may also initiate claims for compensation [11]

宁夏中科生物科技股份有限公司 2025 年第五次临时股东会材料 1 宁夏中科生物科技股份有限公司 2025 年第五次临时股东会议程 一、 宣布会议开幕 二、 宣布到会股东情况 三、 律师确认股东资格合法性 四、 审议表决方法 五、 推选监票人、计票人 六、 审议关于续聘信永中和会计师事务所（特殊普通合伙）为公司 2025 年 度审计机构及内部控制审计机构的议案 七、 审议关于拟增加注册资本暨修订《宁夏中科生物科技股份有限公司章 程》的议案 八、 审议关于拟修订《宁夏中科生物科技股份有限公司高级管理人员年薪 制实施管理办法》的议案 九、 审议关于选举董事的议案 （一）选举刘喜荣先生为宁夏中科生物科技股份有限公司第十届董事会非独 立董事 （二）选举冯战胜先生为宁夏中科生物科技股份有限公司第十届董事会非独 立董事 （三）选举符杰先生为宁夏中科生物科技股份有限公司第十届董事会非独立 董事 （四）选举王炜先生为宁夏中科生物科技股份有限公司第十届董事会非独立 董事 十、 审议关于选举独立董事的议案 （一）选举赵向阳先生为宁夏中科生物科技股份有限公司第十届董事会独立 董事 （二）选举刘辉先生为宁夏中科生物科技股份有限公司第 ...

Group 1: Chemical Sector Performance - The chemical raw materials index increased by 1.62%, while the chemical machinery index decreased by 0.96%, the chemical pharmaceuticals index fell by 1.69%, and the pesticide and fertilizer index rose by 4.21% [1] - The top five rising petrochemical products included folic acid up by 20%, battery-grade lithium carbonate up by 11.08%, nitric acid up by 10.43%, sulfur up by 9.95%, and petroleum coke up by 7.23% [1] - The top five declining petrochemical products were liquid chlorine down by 34%, butadiene down by 7.69%, 2,4-D down by 6.09%, trichloroethylene down by 6.00%, and SBS down by 5.90% [1] Group 2: Oil Sector Performance - The oil processing index rose by 1.39%, while the oil extraction index fell by 0.22%, and the oil trading index increased by 3.44% [1] - International crude oil prices continued to decline, with West Texas Intermediate crude oil futures settling at $56.66 per barrel, down 1.36% from December 12, and Brent crude oil futures settling at $60.47 per barrel, down 1.06% from December 12 [1] Group 3: Capital Market Performance of Listed Chemical Companies - The top five rising listed chemical companies included Sulihua Co., Ltd. up by 30.69%, Xinri Hengli up by 27.48%, Reborn Technology up by 23.25%, Ruihua Tai up by 20.93%, and Shenjian Co., Ltd. up by 20.50% [2] - The top five declining listed chemical companies were Huarong Chemical down by 20.01%, Enjie Co., Ltd. down by 18.36%, Weike Technology down by 13.15%, Jinbantai down by 12.83%, and Xingye Co., Ltd. down by 12.63% [2]

| 证券代码 | 证券简称 | 日涨跌(%) | 笔数 | 环比(%) | | --- | --- | --- | --- | --- | | 600165 | *ST宁科 | 5.01 | 6476 | 6187.38 | | 002788 | 鹭燕医药 | 10.01 | 95978 | 5384.46 | | 603679 | 华体科技 | -9.94 | 76651 | 1860.89 | | 000638 | *ST万方 | 5.02 | 3825 | 1831.82 | | 002231 | *ST奥维 | -2.94 | 8867 | 1375.37 | | 002735 | 王子新材 | 0.00 | 146870 | 1144.34 | | 002204 | 大连重工 | -3.04 | 199859 | 547.95 | | 000551 | 创元科技 | 10.01 | 50479 | 481.09 | | 300276 | 三丰智能 | 8.84 | 68994 | 442.45 | | 601566 | 九牧王 | -3.18 | 132964 | 435.20 | 12月22日每笔 ...

Investment Rating - The report maintains an "Overweight" rating for the basic chemical industry [5] Core Insights - The global semiconductor sales are expected to continue growing in 2025, driven by demand from AI computing, data centers, and smart driving applications. The global semiconductor sales for January to October 2025 are projected to be approximately $612.1 billion, a year-on-year increase of 21.9%, with China's semiconductor sales at about $169.4 billion, up 12.5% [1][22] - The global semiconductor market size is forecasted to reach $700.9 billion in 2025, reflecting an 11.2% year-on-year growth, with the Asia-Pacific region's market size expected to be around $370.6 billion, growing by 9.8% [1][22] - The expansion of wafer production capacity is accelerating, particularly in advanced processes, with a projected compound annual growth rate (CAGR) of 7% from 2024 to 2028 for global 12-inch wafer monthly capacity, expected to reach 11.1 million pieces by 2028 [2][26] - The demand for high-bandwidth memory (HBM) is increasing due to data centers and AI processors, with the global semiconductor materials market expected to reach approximately $70 billion in 2025, a 6% increase year-on-year [3][30] - The advanced process requires higher performance parameters for electronic chemicals, leading to a concentration of industry competition towards leading suppliers capable of meeting these demands [4][32] Summary by Sections Semiconductor Market - AI demand is driving global semiconductor sales growth, with projections for 2025 indicating a significant increase in both global and Chinese markets [1][22] - The semiconductor market is expected to grow to $700.9 billion in 2025, with a further increase to $760.7 billion in 2026 [1][22] Wafer Production Capacity - The global semiconductor wafer production capacity is set to expand significantly, particularly in advanced processes, with a CAGR of 14% for 7nm and below processes from 2024 to 2028 [2][26] Semiconductor Materials - The global semiconductor materials market is projected to grow to $70 billion in 2025, with a notable increase in China's market size to approximately 174.1 billion yuan, reflecting a 21.1% year-on-year growth [3][30] Electronic Chemicals - The advanced semiconductor processes require higher purity and stability in electronic chemicals, leading to a competitive landscape favoring top suppliers with technological and scale advantages [4][32] Investment Recommendations - The report suggests focusing on leading companies in semiconductor materials, particularly those with strong technological capabilities and deep ties to downstream wafer manufacturers [34]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600165 股票简称：*ST宁科（维权） 公告编号：临2025-137 宁夏中科生物科技股份有限公司 股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 宁夏中科生物科技股份有限公司（以下简称：公司）被法院裁定终止重整程序，进入重整计划执行阶 段。根据《中华人民共和国企业破产法》的相关规定，在重整计划执行期间，如公司不执行或不能执行 重整计划，将存在被法院宣告破产的风险。如果公司被宣告破产，公司将被实施破产清算，根据《上海 证券交易所股票上市规则》第9.4.15条的规定，公司股票将面临被终止上市的风险。 ● 宁夏中科生物新材料有限公司（以下简称：中科新材）于2024年2月7日进入停产状态后，根据《上海 证券交易所股票上市规则》的相关规定，公司股票自2024年4月8日起已被上海证券交易所（以下简称： 上交所）实施其他风险警示。虽然中科新材近期已经实现复工复产，但能否实现可持续的正常生产经营 能力，仍有不确定性。 司被宣告破产 ...

证券代码：600165 股票简称：*ST 宁科 公告编号：临 2025-137 宁夏中科生物科技股份有限公司 股票交易风险提示公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容及风险提示： ● 宁夏中科生物科技股份有限公司（以下简称：公司）被法院裁定终止重整 程序，进入重整计划执行阶段。根据《中华人民共和国企业破产法》的相关规 定，在重整计划执行期间，如公司不执行或不能执行重整计划，将存在被法院 宣告破产的风险。如果公司被宣告破产，公司将被实施破产清算，根据《上海 证券交易所股票上市规则》第 9.4.15 条的规定，公司股票将面临被终止上市的 风险。 ● 宁夏中科生物新材料有限公司（以下简称：中科新材）于 2024 年 2 月 7 日进入停产状态后，根据《上海证券交易所股票上市规则》的相关规定，公司 股票自 2024 年 4 月 8 日起已被上海证券交易所（以下简称：上交所）实施其他 风险警示。虽然中科新材近期已经实现复工复产，但能否实现可持续的正常生 产经营能力，仍有不确定性。 ● 因公司 2021 年至 202 ...

截至2025年12月19日收盘，*ST宁科（600165）报收于3.99元，较前一交易日上涨5.0%，最新总市值为 64.47亿元。该股当日开盘3.99元，最高3.99元，最低3.99元，成交额达70.78万元，换手率为0.02%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《*ST宁科股票交易异常波动暨风险提示性公告》 《关于《宁夏中科生物科技股份有限公司股票交易异常波动询证函》的回函》 公司近日发布公告称，其股票于2025年12月16日至18日连续三个交易日收盘价格涨幅偏离值累计超过 12%，构成交易异常波动。公告指出，公司已进入重整计划执行阶段，若未能执行重整计划，存在被宣 告破产及股票终止上市的风险。目前公司股票已被实施其他风险警示，原因包括控股子公司曾停产、连 续三年净利润为负、审计报告存在持续经营重大不确定性以及收到证监会行政处罚等。财务数据显示， 公司2025年第三季度净利润为-25,097.92万元，净资产为-17,918.57万元。公司表示，经自查确认无应披 露而未披露的重大事项。 最新公告列表 ...

受损股民可至新浪股民维权平台登记该公司维权：http://wq.finance.sina.com.cn/ 关注@新浪证券、微信关注新浪券商基金、百度搜索新浪股民维权、访问新浪财经客户端、 新浪财经首页都能找到我们！ 2025年12月18日，上海久诚律师事务所股票索赔律师许峰代理的宁科生物（600165）虚假陈述投资者索 赔案出现重要进展，部分投资者已经收到赔偿款。同日，律师再代理投资者向法院提交一次立案。（许 峰律师专栏） 许峰律师代理的宁科生物投资者索赔案收到法院送达的判决书，投资者获得胜诉。律师团队还在继续推 进后续案件的立案工作，还在继续接受其他投资者的索赔委托。 2024年4月4日，宁科生物公告公司及虞建明收到证监会宁夏监管局下发的《行政处罚决定书》，经查 明，宁科生物违法事实如下： （一）2022年年度报告存在虚假记载 2022年，宁科生物通过其控股子公司宁夏中科生物新材料有限公司（以下简称中科新材），虚增2022年 营业收入7，659.41万元，虚增利润总额7，722.20万元，分别占当期营业收入和利润总额的11.25%、 46.59%，导致宁科生物2022年年度报告存在虚假记载。 （二）未按规定 ...

面对股价的持续异动，*ST宁科连日来发布多份风险提示公告。在12月16日、12月18日和12月19日发布的公告中，公司明 确表示："目前公司基本面没有发生重大变化，也不存在应披露而未披露的重大信息，公司股票交易价格发生较大波动，敬请 广大投资者理性投资，注意投资风险。" 同时，*ST宁科在风险提示中特别强调了公司所面临的多项重大风险。例如，公司被法院裁定终止重整程序，进入重整计 划执行阶段。如公司不执行或不能执行重整计划，将存在被法院宣告破产的风险。如果公司被宣告破产，将面临被终止上市的 风险。公司控股子公司宁夏中科生物新材料有限公司（以下简称"中科新材"）于2024年2月7日进入停产状态，虽然近期已经实 现复工复产，但能否实现可持续的正常生产经营能力，仍有不确定性。 股价异动的背后，是*ST宁科刚刚完成的控股股东及实际控制人变更。12月16日，该公司发布公告称，已于12月15日收到 中国证券登记结算有限责任公司出具的《证券过户登记确认书》，顺利完成资本公积转增股票转入投资人账户事项。根据《重 整计划》，湖南新合新生物医药有限公司（以下简称"湖南新合新"）成为公司新的控股股东，持有*ST宁科3.57亿股股份， ...